World-Changing Drugs from a World-Changing Pioneer
Dr. Alan Shackelford "stunned the medical community"
Doing the Right Thing: Why Dr. Shackelford Became A Research Pioneer
Dr. Shackelford suspected certain cannabinoids could help patients who had lost hope. But pioneering this breakthrough treatment in this young girl had never been done. Colorado’s medical regulators were watching carefully. Not only did that treatment work, it led to something extraordinary…— the creation of a movement to bring a new category of drugs to help the world.
How Dr. Shackelford “Stunned the Medical Community”
Dr. Shackelford was not only vindicated, he’s still changing how the medical community thinks about cannabinoids. He now sits on the very same Colorado Medical Review Board that once questioned him. He is frequently invited to national and state legislatures to talk about the potential of cannabinoids in medicine. His dream is now alive inside Shackelford Pharma, where a world-class team is advancing his work to develop new drugs he hopes will help millions of people.
The Database Big Pharma Wished They Had
After his epilepsy breakthrough — recognized around the world — Dr. Shackelford kept treating patients with cannabinoids. He documented every treatment, condition, dose, and response. He has created a database of over 25,000 real-life patient interactions that has helped us identify many more potential drug candidates. It’s simply unrivaled in the pharmaceutical industry.
INVEST NOW"Dr. Shackelford . . . has developed what many in the industry consider the most advanced database. Now his patience (and his patients) are being rewarded."
Access the Investor Brief
Why the Best Minds in the Industry Are Joining Shackelford Pharma
When pharma companies develop new medicines, they usually rely on theory, anecdotal evidence, computer modeling or petri dish experiments before finding anything with a slim chance of going into human trials. Our database of real-world patient data gives us actual evidence of which formulations have worked with patients. It’s unheard of in the industry.
Our team has collectively developed 43 FDA-approved drugs worth billions in revenue and treated tens of millions of patients.
“Our team has collectively brought 43 FDA-approved drugs to the world. We believe this could be the next one. The database derived from Dr. Shackelford’s real-world treatment of patients is a unique, unprecedented tool that is driving our portfolio strategy and reducing many risks commonly encountered in drug development.”
We’re Taking Our First Drug Candidate to Human Trials
We’ve leveraged Dr. Shackelford’s database to find our first drug opportunity. This treatment could help 1.3 million people with epilepsy who haven’t found a treatment that works. This is a $3-billion market alone. Next we will use our database to develop a dozen more potential drug candidates we have identified. It’s only the beginning, as Dr. Shackelford says.
Investors Benefit When FDA Milestones Are Met
Grew 180% between Phase 2 stage and full FDA approval
$7.2B Exit
Jumped 847% between Phase 2 and Phase 3 completion
Popped 300% higher between Phase 2 and full FDA approval
$1.9B Exit
Our Path to the First FDA Approval is Highly De-risked
- We have approximately 356 patient treatment years of data showing the impact of Dr. Shackelford’s formulation in the real world.
- Dr. Shackelford’s patients achieve 1 year seizure remissions rates approximately 9 times greater than expected.
- Our R&D team has shepherded a combined 43 drugs through the FDA process and our CEO has co-founded 2 biotech unicorns.
Join The Discussion